MKI67 and Miyoshi myopathy: We have further demonstrated that Ki67 expression as a stratification index based on routine pathology biomarkers can easily distinguish the population benefiting from adjuvant chemotherapy for resectable MM and provide an informative basis for the selection of treatment options.